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P ediatric acute encephalitis/encephalopathy (pAEE) is defined as a condition with an acute 
onset of impaired consciousness following an infection 
in childhood.  During the winter of 1998-1999,  an out-
break of pAEE associated with influenza occurred in 
Japan.  After that outbreak,  we conducted a national 
survey of the prevalence and clinical features of pAEE 
and the associated outcomes and prognostic factors [1].  
In all,  202 cases were analyzed,  of which 148 were 
diagnosed as having influenza-associated pAEE based 
on virological evidence.  Influenza-associated pAEE 
developed mainly in children aged ≤ 5 years,  either on 
the day that influenza signs appeared or on the follow-
ing day.  Major signs included impaired consciousness,  
convulsions,  cough,  and vomiting.  In many patients,  
multiple-organ failure developed.  The rates of mortality 
(31.8%) and disability (27.7%) were high.
Since that time,  pAEE has become widely recog-
nized,  arousing the attention of pediatricians world-
wide because influenza-associated pAEE strongly affects 
children’s health management.  Although various 
microbial pathogens other than influenza virus have 
been reported as causative agents of pAEE [2],  the epi-
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We studied the etiology of pediatric acute encephalitis/encephalopathy (pAEE) using epidemiological data 
obtained from a nationwide survey in Japan.  Two-step questionnaires were sent to the pediatric departments of 
hospitals throughout the country in 2007,  querying the number of the cases during 2005-2006 as the first step,  
and asking for the details of clinical information as the second step.  In all,  636 children with pAEE (age ≤ 15 
years) were enrolled.  For the known etiology of pAEE (63.5% of the total cases),  26 microbes and 2 clinical 
entities were listed,  but the etiology of 36.5% remained unknown.  Influenza virus (26.7%),  exanthem subitum 
(12.3%),  and rotavirus (4.1%) were the most common,  and the incidence of pAEE peaked at the age of 1 year.  
This trend was common among all etiologies.  Among the neurological symptoms observed at the onset of 
pAEE,  seizures were observed more often in patients aged ≤ 3 years,  although abnormal speech and behavior 
were also common in older children.  Undesirable outcomes (death and neurological sequelae) occurred at high 
rates in patients with any known etiology other than mycoplasma.  In conclusion,  these findings provide com-
prehensive insight into pAEE in Japan.
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demiological data for pAEE in Japan remain limited [3].  
Therefore,  we conducted the next nationwide survey by 
sending questionnaires to pediatric departments 
throughout Japan in 2007.  We analyzed the epidemio-
logical data of 2005-2006 with an emphasis on pAEE 
etiology.
Patients and Methods
Nationwide survey of pAEE cases during 2005-
2006. A nationwide survey of pAEE was conducted 
at the beginning of 2007 by the Department of Pediatrics 
of Okayama University Graduate School of Medicine,  
Dentistry and Pharmaceutical Sciences,  Japan with 
financial support from the Japanese Ministry of Health,  
Labour and Welfare.  Two-step questionnaires were used 
to determine the number of cases and clinical features of 
pAEE over a 2-year period between January 2005 and 
December 2006.  The first questionnaire was mailed to 
the chiefs of pediatric departments in hospitals with 
pediatric wards throughout Japan,  querying whether 
any patient had been hospitalized for pAEE in their 
hospitals.
In the survey,  pAEE was defined as a condition with 
an acute onset of impaired consciousness following an 
infection.  The second questionnaire,  sent later to hos-
pitals that reported pAEE cases,  included queries about 
the following details: the prefecture in which the hos-
pital was located; patient age; sex; onset date; sur-
vival and neurological outcome; causative microbio-
logical agent; presence/absence of diagnosis of acute 
disseminated encephalomyelitis (ADEM); history of 
vaccination,  febrile seizure,  epilepsy,  and traumatic 
brain injury; symptoms at onset including seizure,  
consciousness disturbance,  abnormal behavior or 
speech,  and fever; laboratory findings; and imaging 
and encephalography data.
The microbiological causative agent was defined 
based on either (1) a positive result of a culture,  antigen 
test,  or viral DNA or RNA polymerase chain reaction 
(PCR) test,  or (2) by significant increases in specific 
antibodies.  We included the clinical diagnosis of exan-
them subitum (ES)-associated encephalopathy as an 
exception.  Of the 2,848 hospitals that received the first 
questionnaire,  1,339 (47.0%) responded.  The second 
questionnaire was sent to 354 hospitals.  Responses were 
received from 248 hospitals.  In all,  717 pAEE cases 
were reported,  including 70 ADEM cases.
Study population and data analysis. We first 
excluded all 70 ADEM cases because the pathology and 
epidemiology of ADEM are well established; it is 
regarded as a distinct pathological entity [4 , 5].  We 
subsequently excluded 11 cases of patients older than 15 
years,  and we included the remaining 636 patients with 
pAEE who were aged ≤ 15 years.  We extracted the fol-
lowing patient data: age; sex; survival and neurologi-
cal outcome; causative microbiological agent; the 
symptoms at the onset including seizure,  consciousness 
disturbance,  abnormal behavior or speech,  and fever.  
The study was approved by the Ethics Committee of the 
Graduate School of Medicine,  Dentistry and Pharma-
ceutical Sciences of Okayama University,  Japan (Ken 
1609-016).
Statistics. After conducting a descriptive analy-
sis,  we first examined the distributions of neurological 
symptoms (including consciousness disturbance,  sei-
zure,  and abnormal speech or behavior) and fever,  in 
all patients and in the patients separated by age group.  
Earlier reports indicated that nearly half of the cases 
show the development of pAEE in infancy and toddler 
years (0-3 years of age) [1 , 3].  We therefore divided the 
patients into 2 age groups: 0-3 and 4-15 years of age at 
the onset of neurological symptoms.  We tested the dif-
ferences in the data of the 2 groups by using chi-
squared tests.
We next evaluated the distributions of symptoms 
separated by causative microbiological agents.  Finally,  
to assess the impact of these microbiological agents on 
patient prognosis,  we assessed the associations using a 
logistic regression model,  adjusting for age (continu-
ous).  In the model,  we estimated the odds ratios (ORs) 
of 2 types: first,  we estimated the ORs for survival (i.e.,  
death vs. survival) and then we estimated the ORs for 
severe sequelae (i.e.,  death or neurological sequelae vs. 
intact survival).  We used a category of “other” causative 
microbiological agents as a reference in the model to 
compare the ORs among seven main causes of pAEE.  
Stata ver. 14 software (Stata Corp.,  College Station,  TX,  
USA) was used for all analyses.  A value of p < 0.05 was 
accepted as significant.  We also estimated the 95% con-
fidence intervals (CIs) using logistic regression analysis.
Results
Table 1 summarizes the sex and etiology of the 
pAEE cases.  The male to female ratio was 1.24.  In all,  
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26 causative agents and two clinical entities (ES and 
sepsis) were defined as the etiology of pAEE.  Among 
the 170 patients with influenza,  86 (50.6%) were 
reportedly infected with influenza A and 42 (24.7%) 
with influenza B.  Among the 78 patients with a diagno-
sis of ES,  27 (34.6%) were diagnosed by an increase of 
specific antibodies to human herpesvirus (HHV)-6; 31 
(39.7%) patients were diagnosed by HHV-6 DNA PCR,  
one patient (1.3%) was diagnosed by HHV-7 DNA PCR,  
and 19 (24.4%) patients were diagnosed based only on 
clinical findings.
Fig. 1 portrays the age distribution and association 
with the etiology of pAEE.  A peak of the incidence was 
found among the patients aged 1 year (Fig. 1A).  
Regarding the month-age distribution,  bimodal peaks 
were found in the patients aged 0 and those around 
12-15 months of age (Fig. 1B).  Influenza-associated 
encephalopathy had a wide age distribution with a peak 
incidence among patients aged 12 months,  ES-associated 
encephalopathy occurred exclusively in infants,  espe-
cially those aged around 12 months (Figs. 1A , B).  
Rotavirus,  adenovirus,  and mumps virus caused 
encephalopathy mainly in infants and toddlers,  whereas 
mycoplasma-associated encephalopathy occurred 
mainly among school-age children (Fig. 1A).  Herpes 
simplex virus (HSV)-associated pAEE constituted a core 
element of the first peak of incidence at the age of 0 
month (Fig. 1B).
Table 2 presents the association between age and 
neurological symptoms at onset.  Seizures were visible 
significantly more frequent in the younger age group,  
whereas abnormal speech and behavior were observed 
significantly less frequently (p < 0.05,  respectively) than 
in the older age group.  Fever was observed in > 90% of 
the patients,  irrespective of age.
Table 3 presents the association between symptoms 
and causative pathogens.  Although seizures were 
observed with a high incidence in younger patients (< 3 
years) with nearly all causes,  HSV-associated pAEE had 
a lower incidence than pAEE associated with other 
causes.  At older ages (4-15 years),  although seizure was 
a main symptom,  abnormal speech and behavior also 
constituted common symptoms for etiologies including 
influenza,  rotavirus,  mycoplasma,  adenovirus,  and 
mumps virus.
Of the 636 pAEE patients,  43 (6.8%) died,  565 sur-
vived (88.8%),  and the survival outcomes of 28 patients 
were unknown.  Although 344 (60.9%) of the 565 
patients who survived manifested no neurological 
sequelae,  215 (38.1%) of them did have neurological 
sequelae but the medical records of six of them did not 
include information related to neurological sequelae.
Table 4 presents the association between etiology 
and outcome of the 602 pAEE patients with known out-
comes.  The patients with main causes other than myco-
plasma had considerably high rates of undesirable out-
comes (e.g.,  death and survival with neurological 
sequelae).  Compared with the pAEE cases with “other” 
causes,  no significantly different probability of undesir-
able outcome was found among the patients with the 
seven main causes.
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Table 1　 Sex and etiology of the pAEE cases (n＝636)
n (%)
Sex
　　　　Male 350 (55.0)
　　　　Female 283 (44.5)
　　　　Unknown 3 (0.5)
Etiology
　　　　Inﬂuenza virus 170 (26.7)
　　　　Exanthem subitum 78 (12.3)
　　　　Rotavirus 26 (4.1)
　　　　Mycoplasma 23 (3.6)
　　　　Adenovirus 18 (2.8)
　　　　Mumps virus 14 (2.2)
　　　　Herpes simplex virus 13 (2.0)
　　　　 Escherichia coli associated with hemo-
lytic-uremic syndrome 8 (1.3)
　　　　Salmonella 6 (0.9)
　　　　Enterovirus 6 (0.9)
　　　　Respiratory syncytial virus 5 (0.8)
　　　　Norovirus 4 (0.6)
　　　　Varicella zoster virus 4 (0.6)
　　　　Measles virus 4 (0.6)
　　　　Epstein-Barr virus 4 (0.6)
　　　　Human metapneumovirus 3 (0.5)
　　　　Streptococcus pyogenes 3 (0.5)
　　　　Sepsis 2 (0.3)
　　　　Pertussis 2 (0.3)
　　　　Haemophilus influenzae 2 (0.3)
　　　　Coxsackievirus 2 (0.3)
　　　　Bartonella 1 (0.2)
　　　　Rubella 1 (0.2)
　　　　Parvovirus 1 (0.2)
　　　　Bacillus cereus 1 (0.2)
　　　　Campylobacter 1 (0.2)
　　　　Echovirus 1 (0.2)
　　　　Cytomegalovirus 1 (0.2)
　　　　Unknown 232 (36.5)
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Fig. 1　 Age distribution of pAEE patients by year (A) and month (B).  Causes are shown in stacked bar charts.
Discussion
Our analyses revealed influenza and ES as the 2 
main causes of pAEE and that the age distribution had a 
peak at 1 year of age.  These findings accorded with 
those of an earlier report [3].  We further examined the 
precise month-age distribution up to 24 months.  The 
number of patients with pAEE increased after 6 months 
of age,  as observed for general febrile illness [6].  Age 
predilection was observed in pAEE associated with HSV 
(at 0 month) and ES (8-15 months).  This information 
could be helpful regarding the choice of laboratory 
examinations for diagnosis.
We observed that the neurological symptoms at the 
onset of pAEE were associated with patient age.  As 
anticipated from the age-dependent incidence of febrile 
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Table 2　 Neurological symptoms and fever at the onset of pAEE
Symptom Total (%)(n＝636)
Age 0-3 years (%)
(n＝353)
Age 4-15 years (%)
(n＝283) p value
＊
Disturbance of consciousness 553 (88.5) 310 (89.9) 243 (86.8) 0.232
Seizure 481 (76.2) 305 (87.1) 176 (62.6) ＜0.001
Abnormal speech and behavior 174 (28.0) 50 (14.5) 124 (44.6) ＜0.001
Fever 581 (92.5) 324 (93.4) 257 (91.5) 0.365
Percentages are calculated among patients with information for each symptom.
＊P values between the 2 age groups.
Table 3　 Association of symptoms with the etiology of pAEE
Symptoms Inﬂuenza ES Rotavirus Mycoplasma Adenovirus Mumps virus HSV Others Etiology unknown
All age groups (n＝170) (n＝78) (n＝26) (n＝23) (n＝18) (n＝14) (n＝13) (n＝62) (n＝232)
Consciousness disturbance 150 (90.9) 66 (84.6) 22 (88) 21 (91.3) 16 (88.9) 13 (92.9) 8 (66.7) 55 (88.7) 202 (88.6)
Seizure 132 (78.6) 74 (94.9) 21 (80.8) 8 (34.8) 11 (61.1) 11 (78.6) 7 (53.9) 41 (66.1) 176 (76.9)
Speech and behavior changes 62 (36.9) 8 (10.3) 5 (19.2) 9 (42.9) 8 (44.4) 6 (42.9) 2 (18.2) 14 (22.6) 60 (26.8)
Fever 166 (99.4) 74 (96.1) 22 (88) 21 (91.3) 18 (100) 14 (100) 12 (92.3) 52 (83.9) 202 (88.2)
Age 0-3 years (n＝80) (n＝77) (n＝18) (n＝3) (n＝10) (n＝6) (n＝7) (n＝30) (n＝122)
Consciousness disturbance 68 (90.7) 66 (85.7) 17 (94.4) 3 (100) 8 (80) 6 (100) 4 (66.7) 27 (90) 111 (92.5)
Seizure 70 (89.7) 74 (96.1) 16 (88.9) 2 (66.7) 7 (70) 6 (100) 4 (57.1) 22 (73.3) 104 (86)
Speech and behavior changes 19 (24.4) 7 (9.1) 1 (5.6) 0 (0) 3 (30) 1 (16.7) 1 (20) 3 (10) 15 (12.7)
Fever 77 (98.7) 74 (97.4) 16 (94.1) 3 (100) 10 (100) 6 (100) 6 (85.7) 25 (83.3) 107 (89.2)
Age 4-15 years (n＝90) (n＝1) (n＝8) (n＝20) (n＝8) (n＝8) (n＝6) (n＝32) (n＝110)
Consciousness disturbance 82 (91.1) 0 (0) 5 (71.4) 18 (90) 8 (100) 7 (87.5) 4 (66.7) 28 (87.5) 91 (84.3)
Seizure 62 (68.9) 0 (0) 5 (62.5) 6 (30) 4 (50) 5 (62.5) 3 (50) 19 (59.4) 72 (66.7)
Speech and behavior changes 43 (47.8) 1 (100) 4 (50) 9 (47.4) 5 (62.5) 5 (62.5) 1 (16.7) 11 (34.4) 45 (42.5)
Fever 89 (100) 0 (0) 6 (75) 18 (90) 8 (100) 8 (100) 6 (100) 27 (84.4) 95 (87.2)
Percentages are calculated among patients with information for each symptom.
ES,  exanthem subitum; HSV,  herpes simplex virus.
Table 4　 Association of outcomes with the etiology of pAEE (n＝602)
Outcomes
Inﬂuenza
(n＝158)
ES
(n＝72)
Rotavirus
(n＝26)
Mycoplasma
(n＝22)
Adenovirus
(n＝17)
Mumps virus
(n＝14)
HSV
(n＝13)
Others
(n＝61)
Etiology unknown
(n＝219)
Death＊ 11 (7.0) 2 (2.8) 1 (3.9) 0 (0) 2 (11.8) 1 (7.1) 1 (7.7) 5 (8.2) 20 (9.1)
Survival with neurological
 sequelae＊
39 (24.7) 31 (43.1) 10 (38.5) 3 (13.6) 6 (35.3) 4 (28.6) 4 (30.8) 20 (32.8) 98 (44.8)
Survival without neurological
 sequelae＊
108 (68.4) 39 (54.2) 15 (57.7) 19 (86.4) 9 (52.9) 9 (64.3) 8 (61.5) 36 (59.0) 101 (46.1)
Death vs. survival＊＊ 0.82 (0.27-2.48) 0.25 (0.05-1.37) 0.4 (0.04-3.62) NE 1.39 (0.24-7.97) 0.83 (0.09-7.77) 0.91 (0.1-8.61) 1 (reference) 1.09 (0.39-3.05)
Death and neurological
 sequelae vs. intact survival＊＊
0.63 (0.34-1.18) 0.83 (0.4-1.7) 0.88 (0.34-2.25) 0.34 (0.09-1.3) 1.16 (0.39-3.49) 0.75 (0.22-2.53) 0.88 (0.25-3.11) 1 (reference) 1.63 (0.91-2.93)
＊Data shown as number (%).
＊＊Data shown as odds ratio (95% conﬁdence interval).  The odds ratio was adjusted for age.
ES,  Exanthem subitum; HSV,  Herpes simplex virus; NE,  not estimated.
seizures [7],  seizures were observed more often in the 
younger patients (≤ 3 years old).  Abnormal speech and 
behavior were more frequent in the older patients (≥ 4 
years old).  These findings seemed to reflect the brain 
development process [7].  We also identified differences 
in neurological symptoms at the onset among the causes 
of pAEE.  The seizure incidence was lower in the HSV-
associated pAEE cases compared to the other causes,  
which might be associated with the age predilection (at 
0 month); the diagnosis of neonatal seizure is rather 
difficult [8].  As has been examined intensively and 
acknowledged widely [9],  abnormal speech and behav-
ior are associated with influenza,  although comparable 
rates were observed for pAEE associated with myco-
plasma,  adenovirus,  and mumps virus.
Our present findings indicate that the rates of mor-
tality and severe neurological sequelae of pAEE were 
high,  as reported earlier from a Japanese study [3].  
Moreover,  the rates of undesirable outcomes were 
dependent on the pAEE etiology.  The mortality rate of 
influenza-associated pAEE was reported initially to be 
as high as around 30% [1].  However,  the correspond-
ing rate was found to be 7.0% in the present study,  
nearly equal to those in recently published reports 
[10 , 11].  This dramatic decrease might be attributable 
to the widespread use of the treatment guidelines from 
the Japanese Ministry of Health,  Labour,  and Welfare 
[12].  The mortality rate and the rates of severe neuro-
logical sequelae of pAEE associated with ES and rotavi-
rus in the present study were nearly identical to those of 
earlier studies [13 , 14].  It might be of interest to ascer-
tain whether the introduction of rotavirus vaccine [15] 
will alter the outcomes.
It is also noteworthy that we detected no signifi-
cantly different odds of undesirable outcomes (e.g.,  
death and neurological sequelae) among the seven main 
etiologies.  This finding likely indicates that the etiology 
alone is not a prognostic factor of pAEE; syndrome 
classification might contribute more to the outcomes 
[3].  In addition,  the measurement of brain injury 
markers such as S-100B and tau protein in cerebrospi-
nal fluid samples might have predictive ability for clini-
cal outcomes in patients with pAEE [16].
This study has several limitations.  First,  as with 
many surveys in Japan,  the response rate to the ques-
tionnaire was not high enough to rule out possible 
non-response bias.  Second,  the survey used for this 
study was outdated.  Third,  the etiology was inferred 
according to the diagnosis by physicians,  among whom 
the diagnostic microbiological testing for pAEE was not 
standardized.
Several rapid antigen detection kits recently became 
available in Japan for the detection of human metap-
neumovirus [17],  norovirus [18],  and respiratory syn-
cytial virus [19].  Moreover,  the loop-mediated isother-
mal amplification method is now available for the 
detection of Mycoplasma pneumoniae [20] and Bordetella 
pertussis [21].  In the current clinical setting,  diagnostic 
microbiological testing is much more facilitated and 
specified than in years past.  In addition,  syndrome 
classification has been introduced with advantages in 
the prediction of clinical outcomes [3].  Future studies 
of the epidemiology of pAEE must adopt viewpoints of 
both etiology and syndrome classification.
In conclusion,  we documented the epidemiological 
distribution of pAEE in Japan over a 2-year period 
between January 2005 and December 2006.  We antici-
pate that the results of the current analysis will provide 
further support for the management and daily clinical 
care of patients with pAEE.
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